Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 01, 2022

SELL
$16.57 - $35.1 $134,846 - $285,643
-8,138 Closed
0 $0
Q1 2022

May 10, 2022

SELL
$31.92 - $47.45 $39,708 - $59,027
-1,244 Reduced 13.26%
8,138 $262,000
Q4 2021

Feb 08, 2022

SELL
$26.23 - $47.86 $19,095 - $34,842
-728 Reduced 7.2%
9,382 $437,000
Q3 2021

Nov 12, 2021

SELL
$23.91 - $29.58 $34,358 - $42,506
-1,437 Reduced 12.44%
10,110 $273,000
Q2 2021

Aug 13, 2021

BUY
$17.9 - $36.1 $25,489 - $51,406
1,424 Added 14.07%
11,547 $296,000
Q1 2021

May 14, 2021

BUY
$30.86 - $44.2 $69,033 - $98,875
2,237 Added 28.37%
10,123 $346,000
Q4 2020

Feb 09, 2021

BUY
$21.59 - $33.95 $170,258 - $267,729
7,886 New
7,886 $267,000

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $258M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.